CREDENCE, DAPA-CKD and EMPA-KIDNEY have consistently shown that SGLT-2 inhibition significantly and importantly reduces the risk of progression of CKD in broad ranges of people with CKD, including in people with diabetic kidney disease and kidney disease of non-diabetic aetiology [1–4]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.